Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp's lead product candidate, ABS-201, is anticipated to generate initial efficacy data in the AGA patient population in the second half of 2026, with further positive outcomes expected as the study progresses toward the 26-week data readout in early 2027. The company's projected revenue net present value (rNPV) has increased to $1.6 billion following the inclusion of ABS-201 in financial forecasts, reflecting a growing confidence in the therapeutic's market potential. With high interest in in-office procedures and strong preclinical evidence supporting ABS-201's unique mechanism of action, Absci is positioned favorably as it approaches key data release points, which represent significant catalysts for stock performance.

Absci Corp faces multiple risks that could negatively impact its stock performance, including challenges related to partnerships, technology implementation, and regulatory approvals, which are critical for the success of its lead product candidate, ABS-201. Additionally, the competitive landscape for therapeutics targeting hair loss indications presents significant hurdles, as high treatment burdens often lead patients to explore alternative, more permanent solutions. Furthermore, potential issues surrounding intellectual property and stock dilution may further undermine investor confidence in the company's future growth prospects.